Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics (NQ: FOLD )

9.700 +0.370 (+3.97%)
Streaming Delayed Price Updated: 2:47 PM EDT, May 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Amicus Therapeutics

< Previous 1 2 3 Next >
Short Volatility Alert: Amicus Therapeutics, Inc.
On Tuesday, shares of Amicus Therapeutics, Inc. (NASDAQ: FOLD) experienced volatile short activity. After the activity, the stock price went up +5.67% to $9.88. The overall... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,... 
Via Benzinga
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Amicus Shares Encouraging Long-Term Data Of AT-GAA Study In Pompe Disease
Amicus Therapeutics Inc (NASDAQ: FOLD) has  
Via Benzinga
7 Biotech Stocks With Key Catalysts for May
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. 
Via InvestorPlace
FDA Extends Review Of Amicus Therapeutics' AT-GAA For The Treatment Of Pompe Disease By Three Months
The U.S. 
Via Benzinga
Recap: Amicus Therapeutics Q1 Earnings
Amicus Therapeutics (NASDAQ:FOLD) reported its Q1 earnings results on Monday, May 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Outlook For Amicus Therapeutics
Amicus Therapeutics (NASDAQ:FOLD) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Amicus... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a... 
Via Benzinga
Amicus Therapeutics Earnings Conference Call Is Coming Up, Here's What You Need To Know
Amicus Therapeutics (NASDAQ:FOLD) will host a conference call at 08:30 AM ET on May 9, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
Gene Therapy Player Amicus Therapeutics Terminates SPAC Merger, Shares Fall
Amicus Therapeutics Inc (NASDAQ: FOLD) has terminated its plans to spin off its gene therapy assets, citing 'existing market conditions.' With "market... 
Via Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
Via Benzinga
Amicus Therapeutics Earnings Preview
Amicus Therapeutics (NASDAQ:FOLD) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 14, 2022
Upgrades According to Seaport Global, the prior rating for Lennar Corp (NYSE: 
Via Benzinga
10 Biggest Price Target Changes For Friday
Keybanc cut Robinhood Markets, Inc. (NASDAQ:HOOD... 
Via Benzinga
60 Biggest Movers From Yesterday
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares surged 57.1% to close at $5.39 on Monday. Zynga Inc. (NASDAQ: ZNGA) rose 40.7% to settle at $8.44 after the company... 
Via Benzinga
Mid-Afternoon Market Update: Dow Tumbles 250 Points; Zynga Shares Spike Higher
Toward the end of trading Monday, the Dow traded down 0.70% to 35,978 while the NASDAQ fell 0.93% to 14,796.51. The S&P also fell, dropping, 0.72% to 4,643.29. The U.S.... 
Via Benzinga
Mid-Day Market Update: Nasdaq Dips 300 Points; Apria Shares Surge
Midway through trading Monday, the Dow traded down 1.23% to 35,787.07 while the NASDAQ fell 2.07% to 14,627.21. The S&P also fell, dropping, 1.52% to 4,605.95. The U.S. has... 
Via Benzinga
45 Stocks Moving In Monday's Mid-Day Session
Gainers Bone Biologics Corporation (NASDAQ: BBLG) shares climbed 71.5% to $5.88. Zynga Inc. (NASDAQ: ZNGA) gained 45.7% to $8.74 after the company announced it will be acquired... 
Via Benzinga
Amicus Therapeutics, inc (FOLD) Q3 2021 Earnings Call Transcript
FOLD earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Benzinga's Top Ratings Upgrades, Downgrades For November 15, 2021
Upgrades For Targa Resources Corp (NYSE: 
Via Benzinga
The Week In SPAC News - Sunday, Oct. 3
In SPAC news this week, Amicus Therapeutics announced its intent to sell its gene therapy unit to ARYA Sciences Acquisition Corp IV, a SPAC sponsored by Perceptive Advisors. 
Via Talk Markets
Perceptive Advisors-Backed SPAC To Acquire Amicus's Gene Therapy Business
Amicus Therapeutics Inc (NASDAQ: FOLD) has agreed to spin off its gene therapy business to Sciences Acquisition Corp IV (NASDAQ: ARYD) and launch genetic... 
Via Benzinga
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
Why Are Amicus Therapeutics Shares Trading Higher Today?
The FDA has accepted for review Amicus Therapeutics Inc's (NASDAQ: FOLD) Biologics License Application (BLA) for cipaglucosidase alfa and the New Drug... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
Upgrades For Cabot Oil & Gas Corp (NYSE:COG),... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Geovax Labs (NASDAQ:GOVX) shares increased by 23.44% to $5.16 during Wednesday's pre-market session. The market value of their outstanding shares is at $32.6... 
Via Benzinga
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Cellectar Biosciences (NASDAQ:CLRB 
Via Benzinga
Is It Time to Buy 5 of the Nasdaq's Worst-Performing Stocks of 2021?
One particular group of stocks is overrepresented among the exchange's biggest losers this year. That's an important detail. 
Via The Motley Fool
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.